Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Inceptive
Inceptive

Inceptive

Series A

RNA design firm using deep learning and high-throughput experiments to create innovative medicines and biotechnologies.

HQ
Palo Alto, CA, US
Founded
2021
Overview
Compare
Fundraising
Employees

Inceptive, founded with the mission to revolutionize the field of biotechnology, focuses on designing RNA molecules using advanced deep learning techniques combined with high-throughput experiments. The company aims to create powerful biological software that enables the rational design of novel and broadly accessible medicines and biotechnologies, pushing the boundaries of what is currently achievable in the field. Their market focus includes pharmaceutical companies and research institutions looking to develop innovative treatments and biotechnological solutions.

Notable individuals affiliated with Inceptive include experts in computational biology and biotechnology, though specific names are not provided. The company has garnered attention for its cutting-edge approach to RNA design, leveraging artificial intelligence to accelerate the development of new therapies. Inceptive's impact is evident in its potential to transform medicine by making advanced biotechnologies more accessible and effective, positioning itself as a leader in the next generation of medical innovation.

Inceptive - Similar Companies

Atomic AI logo

Atomic AI

atomic.ai

Wayfinder Biosciences logo

Wayfinder Biosciences

wayfinderbio.com

Nextrna Therapeutics logo

Nextrna Therapeutics

Rnav8 Bio logo

Rnav8 Bio

Entwine Bio logo

Entwine Bio

entwine.bio

Generate Biomedicines logo

Generate Biomedicines

ReviR Therapeutics logo

ReviR Therapeutics

revirtx.com

Orbital Therapeutics logo

Orbital Therapeutics

Aptah logo

Aptah

aptah-bio.com

Airna logo

Airna

airna.com

EnPlusOne Biosciences logo

EnPlusOne Biosciences

enplusonebio.com

Alltrna logo

Alltrna

alltrna.com

NeuroX1 logo

NeuroX1

neurox1.com

Rnaimmune logo

Rnaimmune

rnaimmune.com

Profluent Bio logo

Profluent Bio

profluent.bio

Inceptive - Quick Facts

Who are Inceptive's competitors?

Companies similar to Inceptive include Atomic AI, Wayfinder Biosciences, Nextrna Therapeutics and Rnav8 Bio.

When was Inceptive founded?

Inceptive was founded in 2021.

Where is Inceptive's headquarters located?

Inceptive's headquarters is located in Palo Alto, CA, US.

When was Inceptive's last funding round?

Inceptive's most recent funding round was for $100M (USD) in September 2023.

How much has Inceptive raised to-date?

As of Sep 7, 2023, Inceptive has raised a total of $120M (USD).

How many employees does Inceptive have?

Inceptive has 29 employees as of Feb 4, 2024.

Inceptive - Classification

Ownership
  • Private Equity
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • United States
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Medicines
  • RNA Design
Tags
  • Biotech
  • Healthtech
  • Research
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software